Search clinical trials for: Lilly glucagon

Total 549 results

Xeris Pharmaceuticals

Completed

Safety and Efficacy of G-Pen Compared to Lilly Glucagon for Hypoglycemia Rescue in Adult Type 1 Diabetics

Hypoglycemia | Diabetes Mellitus, Type 1

United States, Canada
Zealand Pharma

Completed

ZP4207(Dasiglucagon) Administered to T1D Patients to Assess the PK and PD Compared to Marketed Glucagon

Diabetes Mellitus Type 1

Germany
Steven J. Russell, MD, PhD

Completed

Equivalence of A Stable Liquid Glucagon Formulation With Freshly Reconstituted Lyophilized Glucagon

Type 1 Diabetes

United States
Xeris Pharmaceuticals
SGS S.A.; Integrated Medical Development

Completed

G-Pen™ Compared to Lilly Glucagon for Hypoglycemia Rescue in Adults With Type 1 Diabetes

Type 1 Diabetes Mellitus | Severe Hypoglycemia | Insulin Hypoglycemia

United States, Canada
Biodel

Completed

Pharmacokinetics and Pharmacodynamics of BIOD-961 vs. Marketed Glucagons

Hypoglycemia
Abvance Therapeutics
T1D Exchange, United States

Completed

A Trial to Investigate Hyperglycemic and Hypoglycemic Excursions in Subjects With Type 1 Diabetes

Type 1 Diabetes Mellitus With Hypoglycemia

United States
Zosano Pharma Corporation

Completed

Safety and Efficacy of ZP-Glucagon to Injectable Glucagon for Hypoglycemia

Hypoglycemia

Australia
Massachusetts General Hospital
Boston University

Terminated

The iLet Introduction Study: A Feasibility Study of the iLet, a Fully Integrated Bihormonal Bionic Pancreas

Diabetes Mellitus Type 1

United States
Steno Diabetes Center Copenhagen

Recruiting

Low-Dose Glucagon and Advanced Hybrid Closed-Loop System for Prevention of Exercise-Induced Hypoglycaemia in People With Type 1 Diabetes (The HYPO-AVOID)

Hypoglycemia | Type 1 Diabetes

Denmark
Xeris Pharmaceuticals
Empiristat, Inc.

Completed

G-Pen Compared to Glucagen Hypokit for Severe Hypoglycemia Rescue in Adults With Type 1 Diabetes

Type 1 Diabetes Mellitus | Severe Hypoglycemia | Insulin Hypoglycemia

United States, Canada, Austria
Eli Lilly and Company
Locemia Solutions ULC

Completed

Evaluate the Immunogenicity of a Novel Glucagon Formulation

Diabetes Mellitus | Drug-specific Antibodies

Canada
Zealand Pharma

Completed

Single Doses of ZP4207 Adm. sc to Hypoglycemic TD1 pt. to Describe the PK and PD of ZP4207 as Comp. to Marketed Glucagon

Hypoglycemia

Germany
Sanofi

Completed

A Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Doses of SAR438544 in Comparison to Placebo and Glucagon in Healthy Subjects and Type 1 Diabetes Mellitus Patients

Type 1 Diabetes Mellitus

United States
Eli Lilly and Company

Completed

A Study of Nasal Glucagon in Participants With Type 1 Diabetes Mellitus

Hypoglycemia | Diabetes Mellitus, Type 1

Germany
Eli Lilly and Company
Jaeb Center for Health Research; Locemia Solutions ULC

Completed

Assessment of Intranasal Glucagon in Children and Adolescents With Type 1 Diabetes

Diabetes Mellitus, Type 1

United States
Charite University, Berlin, Germany

Unknown

Glucagon Modulation of Ghrelin Secretion

Obesity | Diabetes Mellitus, Type 1 | Healthy Subjects

Germany
Eli Lilly and Company
Locemia Solutions ULC; T1D Exchange Clinic Network Coordinating Center

Completed

Efficacy and Safety of Nasal Glucagon for Treatment of Hypoglycemia in Adults

Diabetes Mellitus, Type 1

United States
Xeris Pharmaceuticals
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Emissary...

Completed

Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of G-Pen(TM) (Glucagon Injection) to Treat Severe Hypoglycemia

Hypoglycemia

United States
Steno Diabetes Center Copenhagen

Completed

Low-dose Glucagon for Prevention of Exercise-Induced Hypoglycemia in People With Type 1 Diabetes

Hypoglycemia | Type 1 Diabetes

Denmark
Zealand Pharma
SynteractHCR

Completed

A Trial to Evaluate the Immunogenicity of Dasiglucagon and GlucaGen in Patients With Type 1 Diabetes Mellitus

Hypoglycemia | Diabetes Mellitus, Type 1

United States, Austria, Canada, Germany
Eli Lilly and Company

Completed

A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus

Diabetes Mellitus

Japan
Adocia

Completed

A Trial to Investigate the Safety and the Pharmacokinetic, Pharmacodynamic Characteristics of Two BioChaperone® Glucagon Formulations Compared to Marketed GlucaGen® in Subjects With T1DM

Type 1 Diabetes Mellitus

Germany
Xeris Pharmaceuticals
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Emissary...

Completed

PK/PD Study With G-Pump (Glucagon Infusion) in T1DM Patients

Hypoglycemia

United States
Institut de Recherches Cliniques de Montreal

Completed

Closed-loop Control of Postprandial Glucose Levels in Adults With Type 1 Diabetes

Type 1 Diabetes

Canada
Fresenius Kabi USA, LLC

Completed

Bioequivalence of Fresenius Kabi USA, LLC Glucagon for SC Injection Compared to Glucagon for Injection (Bedford Laboratories)

Hypoglycemia

United States
Sanofi

Withdrawn

A Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of a Single Dose of SAR438544 in Comparison to Glucagon in Type 1 Diabetes Mellitus Patients Under Induced Hypoglycemia

Type 1 Diabetes Mellitus
Zealand Pharma

Completed

A Trial to Confirm the Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in Type 1 Diabetes Subjects

Hypoglycemia | Diabetes Mellitus, Type 1

Canada, United States, Austria, Germany
Hospira, now a wholly owned subsidiary of Pfizer

Completed

Pharmacokinetics (PK) and Pharmacodynamics (PD) of Mayne Glucagon for Injection Compared With Glucagen® (Novo Nordisk) in Healthy Volunteers

Hypoglycemia

United Kingdom
Université Catholique de Louvain
Fonds National de la Recherche Scientifique; BESPEED

Active, not recruiting

Phenotypic and Genotypic Characterization of New-onset Type I Diabetes (DIATAG)

Type1diabetes

Belgium
Steno Diabetes Center Copenhagen
University of Copenhagen

Completed

Hepatic Metabolic Changes in Response to Glucagon Infusion

Diabetes Mellitus | Non-Alcoholic Fatty Liver Disease | Total Pancreatectomy

Denmark
Legacy Health System
Juvenile Diabetes Research Foundation; Oregon Health and Science University

Completed

Safety Study of Repeated Doses of Glucagon on Animal Starch in the Liver

Type 1 Diabetes Mellitus

United States
Xeris Pharmaceuticals

Completed

Glucagon Ready-to-Use (RTU) for Prevention of Exercise-Induced Hypoglycemia During Aerobic Exercise in Adults With T1D

Hypoglycemia

Canada
Novo Nordisk A/S

Completed

First Research Study to Compare a Possible New Medicine NNC9204-1513 to the Medicine Glucagon, in Healthy People.

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1

Germany
Inreda Diabetic B.V.

Withdrawn

A Stable Glucagon Analog Administered by a Bihormonal Closed Loop System (STABLE-1)

Diabetes Mellitus, Type 1

Netherlands
University Hospital Bispebjerg and Frederiksberg

Completed

Glucagon's Cardiovascular Effects With and Without Beta-blocker-induced Cardioinhibition (GLUCAGON)

Drug Overdose | Overdose of Beta-adrenergic Blocking Drug

Denmark
Eli Lilly and Company
Locemia Solutions ULC

Completed

Safety and Efficacy of a Novel Glucagon Formulation in Type 1 Diabetic Patients Following Insulin-induced Hypoglycemia (AMG102)

Hypoglycemia

Canada
Legacy Health System
Juvenile Diabetes Research Foundation; Oregon Health and Science University

Completed

Physiologic Response to Glucagon at Varying Insulin Levels

Type 1 Diabetes Mellitus

United States
Insel Gruppe AG, University Hospital Bern

Withdrawn

Micro Glucagon During Exercise in Type 1 Diabetes

Hypoglycemia | Type 1 Diabetes

Switzerland
Massachusetts General Hospital
Joslin Diabetes Center

Completed

Post Bariatric Closed Loop Glucagon Trial

Hypoglycemia

United States
The University of Texas Health Science Center at...
South Texas Veterans Health Care System

Active, not recruiting

Effect of Physiologic Hyperglucogonemia on Adipocyte Metabolism (Glucagon)

Insulin Sensitivity

United States
Steno Diabetes Center Copenhagen
Herlev Hospital; Technical University of Denmark

Completed

Dual-Hormone Closed-Loop Glucose Control in Adolescents With Type 1 Diabetes (DHCL2021)

Type 1 Diabetes

Denmark
Hvidovre University Hospital
Technical University of Denmark

Completed

The Impact of Subcutaneous Glucagon Before, During and After Exercise a Study in Patients With Type 1 Diabetes Mellitus

Type 1 Diabetes Mellitus

Denmark
Erin McCreary
University of Pittsburgh

Terminated

UPMC OPTIMISE-C19 Trial, a COVID-19 Study (OPTIMISE-C19)

Covid19

United States
Xeris Pharmaceuticals
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Completed

CSI-Glucagon for Prevention of Hypoglycemia in Children With Congenital Hyperinsulinism

Congenital Hyperinsulinism

United States
Xeris Pharmaceuticals
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Emissary...

Completed

Safety and Efficacy Study of Mini-Dose Glucagon (G-Pen Mini) in Patients With Type 1 Diabetes

Hypoglycemia

United States
Zealand Pharma

Completed

Trial to Confirm the Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in T1DM Children

Hypoglycemia

United States, Germany, Slovenia
Joslin Diabetes Center
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National... and other collaborators

Completed

Closed-Loop Glucagon Pump for Treatment of Post-Bariatric Hypoglycemia

Post-bariatric Hypoglycemia

United States
Xeris Pharmaceuticals
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Completed

Delivery of G-Pump™ (Glucagon Infusion) From an OmniPod® to Prevent Hypoglycemia in Post-Bariatric Surgery Patients

Hypoglycemia | Complications of Bariatric Procedures

United States
University Health Network, Toronto

Completed

Acute Regulation of Intestinal and Hepatic Lipoprotein Production by Glucagon (Glucagon)

Diabetes

Canada
Eli Lilly and Company

Completed

Clinical Usability of Nasal Glucagon in Treatment of Hypoglycemia in Children and Adolescents

Diabetes Mellitus | Hypoglycemia

United States

Search clinical trials for: Lilly glucagon

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Zimbabwe

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations